The study is a prospective, randomized trial of the efficacy in the prevention of recurrent stroke and/or TIA of percutaneous PFO closure using the Amplatzer PFO Occluder (AGA Medical Corporation, USA) compared to medical treatment in patients with presumed paradoxical embolism.